Our peptides

We offer a range of specialized services tailored to meet your individual needs.

WhatsApp us to order 

Tirzepatide

£100.00

Tirzepatide (brand names Mounjaro and Zepbound) is a once-weekly injectable GIP and GLP-1 receptor agonist used to treat type 2 diabetes and chronic weight management. By reducing appetite and slowing stomach emptying, it helps adults lose up to 20% of their body weight and improves glycemic control. Common side effects include nausea, diarrhea, vomiting, and constipation.BNF +5

Key Details

    • Uses: Treatment of type 2 diabetes and long-term weight management in adults with obesity or overweight (BMI
      ≥
      ≥
      27-30
      kg/m2
      𝑘𝑔/𝑚2
      ).

 

  • Administration: Self-administered subcutaneous (under the skin) injection, usually in the abdomen, thigh, or upper arm, once weekly.
  • Dosage: Starts at 2.5 mg, with titration in 2.5 mg increments every 4 weeks to a maintenance dose of 5, 10, or 15 mg.
  • Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, injection site reactions, and potential fatigue.
  • Long-Term Effects: Studies indicate no unexpected safety signals over a 176-week period. It may also reduce the risk of developing type 2 diabetes by 94% in high-risk individuals.
  • Contraindications: Should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
    NHS England +5

 

 

 

 

 

 

 

Important Information
Tirzepatide is most effective when paired with lifestyle changes, such as a reduced-calorie diet and increased physical activity. It may interact with oral contraceptives and other diabetes medications

+ See details

Retatrutide

£100.00

Retatrutide is an experimental, once-weekly injectable "triple agonist" (GIP, GLP-1, and glucagon receptor) developed by Eli Lilly for obesity and type 2 diabetes. Currently in Phase 3 trials, it has shown superior weight loss results (up to ~24% in 48 weeks) compared to current GLP-1s, earning it the nickname "triple-G".NEJM +4

Key Details About Retatrutide:

    • Mechanism of Action: It mimics three hormones: GLP-1 (appetite suppression), GIP (improves insulin response), and Glucagon (increases energy expenditure/fat burning).

 

  • Trial Results: Phase 2 studies showed up to 24.2% body weight reduction in participants after 48 weeks of treatment at higher doses, often referred to as "triple G".
  • Availability: It is not yet FDA approved or available to the public. Phase 3 trials are expected to be completed in 2026, with anticipation of approval following soon after.
  • Side Effects: Similar to other weight loss medications, it may cause nausea, diarrhea, vomiting, and constipation.
  • Compared to Others: It is different from semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) because it targets three receptors instead of one or two.

 

 

+ See details